Transition of care after hospital discharge remains a high-risk period, particularly for insulin-treated individuals with T2D, who often experience therapeutic inertia and remain vulnerable to hypoglycemia, as previously reported by Tian et al. [41], a systematic review in which only one relevant article assessing CGM use at discharge was found, highlighting the limited evidence base and multiple barriers to implementation in this population. The gene discussed is INS; the disease is Hypoglycemia.